FY24 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science Award Notice
ID: FDABAA-24-00123_AwardType: Special Notice
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFFOOD AND DRUG ADMINISTRATIONFDA Office of Acquisitions and Grants ServicesRockville, MD, 20857, USA

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

PSC

GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; BASIC RESEARCH (AJ11)

Original Source

https://sam.gov/opp/2d8727abeb8541688a9f24eda6852615/view
Timeline
    Description

    The Department of Health and Human Services, through the Food and Drug Administration (FDA), has announced the FY24 Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science. This opportunity aims to support innovative research projects that enhance regulatory science, with a focus on health, medical, and biotechnology advancements. The awarded contracts, totaling over $24 million, cover a range of critical topics including drug safety, gene therapy, and methodologies for assessing pediatric opioid exposure, reflecting the federal government's commitment to fostering research initiatives that improve healthcare delivery and regulatory processes. Interested parties can contact Ian Weiss at Ian.Weiss@fda.hhs.gov or by phone at 301-796-5728 for further information.

    Point(s) of Contact
    Ian Weiss
    (301) 796-5728
    Ian.Weiss@fda.hhs.gov
    Files
    Title
    Posted
    BAA_AwardedFY24.pdf
    The government file details awarded contracts from various agencies, primarily focused on health, medical, and regulatory research. It lists multiple awards, including the contract number, obligated amount, and recipient information. Key projects include the development of endpoints for atopic dermatitis, interactive lab-test driven discovery engines, and methodologies for assessing opioid exposure in pediatric populations. Awardees such as academic institutions and private companies are allocated significant funding, indicating federal investment in cutting-edge health research and technology. Notably, the contracts span diverse topics from real-world evidence for drug safety to advancements in gene therapy. The total obligated amount for these contracts exceeds $24 million, reflecting a strategic emphasis on innovation and patient engagement within the healthcare sector. Overall, the document illustrates the federal government's commitment to fostering research initiatives that enhance healthcare delivery and regulatory processes.
    BAAwardedFY24.pdf
    The document outlines a series of federal contracts awarded primarily for research projects under the Center for Drug Evaluation and Research (CDER) and other agencies. It lists various awards, detailing their contract numbers, obligated amounts, total estimated values, awardee names and addresses, and project titles. The contracts cover diverse topics, such as developing therapeutic tools for T cell assays, reviewing opioid impact on pediatric populations, and enhancing regulatory decision-making through real-world data analysis. The total amount obligated across all contracts is approximately $20.6 million, with the estimated total value exceeding $31 million. These projects reflect the government's focus on improving public health and regulatory processes through innovative research, emphasizing collaboration with academic institutions and organizations to address pressing health issues. The data illustrates the government's ongoing commitment to advancing medical research and ensuring the safety and efficacy of drugs and devices through funding and support.
    Similar Opportunities
    FY25 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is soliciting proposals through the FY25 Broad Agency Announcement (BAA) aimed at advancing regulatory science and innovation. This opportunity invites organizations, particularly small businesses, to submit research and development proposals that address critical areas such as alternative drug development methods, advanced manufacturing technologies, and predictive toxicology, with a strong emphasis on including diverse populations in research. Proposals must be submitted by February 24, 2025, and will undergo a two-tier evaluation process, with the potential for multiple contracts awarded based on proposal quality and funding availability. Interested parties can contact Ian Weiss at Ian.Weiss@fda.hhs.gov or by phone at 301-796-5728 for further information.
    Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority (BARDA), is soliciting proposals under the Broad Agency Announcement (BAA) BAA-23-100-SOL-00004 for advanced research and development of Medical Countermeasures (MCMs) aimed at addressing public health threats such as chemical, biological, radiological, and nuclear (CBRN) incidents, as well as emerging infectious diseases and pandemic influenza. The initiative seeks to foster public-private partnerships to enhance the development and responsiveness of life-saving MCMs, emphasizing the importance of technological maturity, regulatory compliance, and manufacturing standards in the evaluation process. This opportunity is critical for strengthening national health security and improving preparedness for future public health emergencies, with an open submission period running until September 25, 2028, at 4:30 PM Eastern Time. Interested parties can direct inquiries to BARDA-BAA@hhs.gov for further information.
    2026 NIAID DMID Omnibus Broad Agency Announcement
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and specifically the National Institute of Allergy and Infectious Diseases (NIAID), is soliciting proposals for the 2026 DMID Omnibus Broad Agency Announcement (BAA) aimed at advancing research and development of medical countermeasures against antimicrobial-resistant pathogens and viruses with pandemic potential. The BAA encompasses two primary research areas: the development of therapeutics, vaccines, and diagnostics for antimicrobial-resistant bacterial and fungal pathogens, and the creation of direct-acting antivirals for viral families of pandemic potential. This initiative is critical for addressing public health challenges related to infectious diseases and enhancing biodefense capabilities. Proposals for Research Area 001 are due by February 21, 2025, while those for Research Area 002 are due by January 21, 2025. Interested parties can reach out to primary contact Swee L. Teo at teosl@niaid.nih.gov or 240-669-5173 for further information.
    FDA Regulated Products Sampling Services
    Active
    Health And Human Services, Department Of
    The U.S. Food and Drug Administration (FDA) is seeking qualified vendors to provide Sampling Services for FDA-regulated products through a Sources Sought Notice (Ref No. 75F40125R00032). The primary objective of this procurement is to identify capable businesses that can collect physical samples of food, drugs, medical devices, and other products for laboratory analysis, ensuring safety and verifying labeling accuracy. This initiative is crucial for the FDA's regulatory oversight, as it supports the monitoring of product safety and quality, which may include both domestic and imported goods. Interested parties must submit their responses by January 9, 2025, and can contact Amanda Lusk at Amanda.Lusk@fda.hhs.gov or Nicholas Bisher at Nicholas.Bisher@fda.hhs.gov for further information.
    BARDA DRIVe EZ-BAA (EZBAA - 22-100-SOL-00003)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Office of Biomedical Advanced Research and Development Authority (BARDA), is soliciting proposals under the Easy Broad Agency Announcement (EZ-BAA) BAA-22-100-SOL-00003, which focuses on innovative medical countermeasures (MCMs) to enhance public health preparedness against various threats, including infectious diseases and chemical agents. The initiative invites submissions across multiple Areas of Interest (AOIs), including but not limited to vaccine innovations, diagnostic technologies, and therapeutic solutions for acute radiation syndrome and chemical threats. This opportunity is critical for advancing biomedical research and developing effective responses to health emergencies, with multiple awards anticipated based on scientific merit and funding availability. Interested parties must register on SAM.gov and submit their abstracts by specified deadlines, with key submission dates ranging from March 15, 2024, to May 31, 2024, depending on the AOI. For further inquiries, respondents can contact Aarati Singal or Lara Emmons at DRIVeAcquisitions@hhs.gov.
    Pre-Solicitation FY 2025 CDC OS Emerging Public Health Priorities BAA
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), is preparing to issue a Fiscal Year 2025 Broad Agency Announcement (BAA) for Applied Research aimed at addressing Emerging Public Health Priorities. This initiative seeks innovative research proposals in various areas, including infectious disease surveillance, wastewater surveillance, and substance use disorder recovery, to enhance public health strategies and responses to emerging threats. The BAA will be open for full and open competition, with a tentative issuance date of December 30, 2024, and a due date for concept papers set for January 30, 2025. Interested contractors must ensure they are registered in the System for Award Management (SAM) to be eligible for award, and further details will be available on SAM.gov.
    FY2025 CDC NIOSH Mine Safety and Health Research Broad Agency Announcement
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), is issuing a Broad Agency Announcement (BAA) for the Fiscal Year 2025 focused on enhancing mine safety and health through innovative research and development. The primary objective is to solicit proposals for technologies that address safety and health issues in mining environments, particularly those that can be adapted from other industries or are still in the prototype phase. This initiative is crucial for advancing occupational safety in the mining sector, with a total funding range of $2-5 million anticipated to support 6-10 contracts averaging between $200,000 and $300,000 each. Interested parties must submit concept papers by January 20, 2025, and can direct inquiries to Eugene Marrone at xve9@cdc.gov for further clarification on the solicitation requirements.
    Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is soliciting proposals for Chemistry, Manufacturing, and Controls (CMC) services related to the development of drug products. The objective of this procurement is to secure high-quality formulated drug products to support preclinical, IND-enabling, and clinical studies, ensuring compliance with current Good Manufacturing Practices (cGMP). This initiative is critical for advancing therapeutic development and enhancing the drug development pipeline, which is vital for public health. Proposals are due by February 3, 2025, with a contract period extending from September 30, 2025, to July 31, 2031, and a maximum funding amount of $49,885,703. Interested parties can reach out to Michelle Cecilia at michelle.cecilia@nih.gov or Valerie Whipple at valerie.whipple@nih.gov for further information.
    FY25 Long Range Broad Agency Announcement (BAA) for Navy and Marine Corps Science and Technology
    Active
    Dept Of Defense
    The Department of Defense, through the Office of Naval Research, is soliciting proposals for the FY25 Long Range Broad Agency Announcement (BAA) aimed at advancing Navy and Marine Corps science and technology initiatives. This opportunity invites submissions from a diverse range of sources, including academia, industry, and the research community, to support long-range science and technology projects that enhance operational capabilities. The BAA emphasizes the importance of competitive funding for innovative research across various science and engineering disciplines, encouraging participation from both small and large businesses. Interested parties can reach out to Christine Williams at christine.m.williams2.civ@us.navy.mil for further details regarding proposal submissions and funding considerations.
    Office-Wide Innovative Solutions Opening for Health Science Futures (HSF)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health's Advanced Research Projects Agency for Health (ARPA-H), is soliciting proposals for the Innovative Solutions Opening (ISO) aimed at advancing healthcare technologies. This initiative seeks innovative, disease-agnostic research projects that can significantly improve health outcomes, focusing on areas such as maternal and fetal health, genetic therapies, and novel diagnostic tools. The solicitation emphasizes the development of transformative solutions rather than incremental research, with submissions required to follow a two-step process: an initial solution summary followed by a full proposal based on feedback received. Interested parties must submit their solution summaries by March 3, 2029, via the designated ARPA-H portal, and are encouraged to review the detailed submission guidelines outlined in the provided documentation.